4-(dimethylamino)-N,N-bis(octadec-9-enyl)butanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-(dimethylamino)-N,N-bis(octadec-9-enyl)butanamide
• 化学式: C₄₂H₈₂N₂O
• 分子量: 631.1
• InChiKey: ZJSBRJGFFMUNQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.9
• 重原子数：
  45
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF<br/>[FR] LIPIDES CATIONIQUES TRIALKYLÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PROTIVA BIOTHERAPEUTICS INC

  公开号：WO2013126803A1

  公开（公告）日：2013-08-29

  The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

  本发明提供了用于将治疗剂传递给细胞的组合物和方法。具体包括新颖的三烷基阳离子脂质和核酸-脂质颗粒，这些颗粒能够有效地封装核酸并将封装的核酸有效地传递给体内的细胞。本发明的组合物非常有效，因此可以在相对较低的剂量下有效地降低特定靶蛋白的表达。
• [EN] IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] LIPIDES CATIONIQUES ET PROCÉDÉS AMÉLIORÉS POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES
  申请人：PROTIVA BIOTHERAPEUTICS INC

  公开号：WO2011000106A1

  公开（公告）日：2011-01-06

  The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

  本发明提供了用于将治疗剂传递到细胞的组合物和方法。具体包括新型阳离子脂质和核酸-脂质颗粒，它们能够有效地封装核酸并将封装的核酸有效地传递到体内的细胞中。本发明的组合物具有很高的效力，因此可以在相对较低的剂量下有效地降低特定靶蛋白的表达。此外，本发明的组合物和方法与先前已知的组合物和方法相比，毒性较低，提供更高的治疗指数。
• [EN] METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS<br/>[FR] PROCÉDÉS DE MODIFICATION DE L'EXPRESSION GÉNIQUE PAR PERTURBATION DE MULTIMÈRES DU FACTEUR DE TRANSCRIPTION QUI STRUCTURENT LES BOUCLES RÉGULATRICES
  申请人：WHITEHEAD INST BIOMEDICAL RES

  公开号：WO2018129544A1

  公开（公告）日：2018-07-12

  The invention relates to methods of modulating the expression of one or more genes in a cell by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops, and thereby modulating the expression of the one or more genes. The invention also relates to treating diseases and conditions involving aberrant gene expression by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops. The invention also relates to methods for screening for compounds that modulate expression of one or more genes in a cell.

  该发明涉及通过调节转录因子的多聚化和/或调节增强子-启动子DNA环的形成，从而调节细胞中一个或多个基因的表达的方法。该发明还涉及通过调节转录因子的多聚化和/或调节增强子-启动子DNA环的形成来治疗涉及异常基因表达的疾病和病况。该发明还涉及筛选调节细胞中一个或多个基因表达的化合物的方法。
• LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
  申请人：Sirna Therapeutics, Inc.

  公开号：EP2104740A2

  公开（公告）日：2009-09-30
• SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA
  申请人：Protiva Biotherapeutics Inc.

  公开号：EP2238251A1

  公开（公告）日：2010-10-13